#1 Clinical Trials Search in Europe

Betibeglogene Autotemcel

This article discusses a clinical trial investigating the long-term effects of Betibeglogene Autotemcel, a gene therapy drug for patients with transfusion-dependent beta-thalassemia. The study aims to monitor the safety and effectiveness of this innovative treatment over an extended period, providing valuable insights into its potential as a groundbreaking therapy for this genetic blood disorder.

Table of Contents

What is BETIBEGLOGENE AUTOTEMCEL?

BETIBEGLOGENE AUTOTEMCEL is a groundbreaking gene therapy drug designed to treat patients with transfusion-dependent β-thalassemia (TDT). It is also known by several other names, including:

  • Autologous CD34+ cell enriched population that contains hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the beta-A-T87Q-globin gene
  • Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene
  • Autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene
This therapy is classified as an advanced therapy medicinal product (ATMP) and specifically as a gene therapy.[1]

How Does It Work?

BETIBEGLOGENE AUTOTEMCEL works by modifying the patient’s own stem cells to produce functional hemoglobin. Here’s a simplified explanation of the process:

  1. Doctors collect CD34+ hematopoietic stem cells (blood-forming cells) from the patient through a process called apheresis.
  2. These cells are then genetically modified in a laboratory using a lentiviral vector (a type of virus used to deliver genetic material) that carries a functional beta-A-T87Q-globin gene.
  3. The modified cells, now containing the therapeutic gene, are then infused back into the patient.
  4. Once in the patient’s body, these cells begin to produce functional hemoglobin, potentially reducing or eliminating the need for blood transfusions.
This approach is known as ex vivo gene therapy, meaning the genetic modification occurs outside the body.[1]

What Condition Does It Treat?

BETIBEGLOGENE AUTOTEMCEL is designed to treat transfusion-dependent β-thalassemia (TDT). β-thalassemia is a genetic blood disorder that reduces the production of hemoglobin, the protein in red blood cells that carries oxygen. In its severe form, it requires regular blood transfusions for survival, hence the term “transfusion-dependent.” Patients with TDT typically need lifelong, regular blood transfusions to maintain adequate hemoglobin levels. This can lead to complications such as iron overload, which can damage organs over time.[1]

Clinical Trial Information

The information provided is from a long-term follow-up study of patients who have received BETIBEGLOGENE AUTOTEMCEL in previous clinical trials. This study aims to monitor the long-term safety and effectiveness of the therapy. Key points about the trial:

  • It is a Phase 3 trial, which is typically one of the final stages before a treatment can be approved for general use.
  • Participants must have been previously treated with BETIBEGLOGENE AUTOTEMCEL in a bluebird bio-sponsored clinical study for transfusion-dependent β-thalassemia.
  • There are no exclusion criteria for this study, meaning all patients who received the therapy in previous studies are eligible to participate in this long-term follow-up.
[1]

Safety and Efficacy Monitoring

The study is closely monitoring both the safety and effectiveness of BETIBEGLOGENE AUTOTEMCEL over the long term. Key areas being observed include:

Safety Monitoring:

  • Development of malignancies (cancers)
  • Immune-related adverse events (such as autoimmune disorders, graft-versus-host disease, opportunistic infections, HIV)
  • New or worsening blood disorders
  • New or worsening neurological disorders

Efficacy Monitoring:

  • Expression of the therapeutic β-A-T87Q-globin in the blood
  • Achievement and maintenance of transfusion independence
  • Reduction in the need for blood transfusions
  • Hemoglobin levels over time
  • Iron levels in the body
  • Use of iron chelation therapy (a treatment to remove excess iron from the body)
  • Improvements in the body’s ability to produce healthy red blood cells
[1]

Potential Benefits

While the long-term effects are still being studied, potential benefits of BETIBEGLOGENE AUTOTEMCEL may include:

  • Transfusion Independence: Some patients may no longer need regular blood transfusions.
  • Improved Hemoglobin Levels: The therapy aims to increase the production of functional hemoglobin.
  • Reduced Iron Overload: With fewer or no transfusions, the risk of iron overload may decrease.
  • Improved Quality of Life: The study is measuring changes in health-related quality of life using various assessment tools.
It’s important to note that these potential benefits are being evaluated in the ongoing study, and individual results may vary.[1]

Administration

BETIBEGLOGENE AUTOTEMCEL is administered as a dispersion for infusion. This means it’s given intravenously (through a vein) in a liquid form. The treatment is typically given once, but patients are monitored for an extended period to assess its long-term effects and safety. As this is an advanced therapy, it would be administered in specialized medical centers with expertise in gene therapies and the treatment of β-thalassemia.[1]

Aspect Details
Study Type Phase 3 long-term follow-up
Condition Transfusion-dependent beta-thalassemia
Intervention Betibeglogene Autotemcel (gene therapy)
Primary Endpoints Malignancies, immune-related adverse events, hematologic disorders, neurologic disorders
Secondary Endpoints Transfusion independence, hemoglobin levels, iron burden, quality of life
Follow-up Duration Up to 15 years post-treatment
Eligibility Previously treated with Betibeglogene Autotemcel in a bluebird bio-sponsored study

FAQ

  • What is Betibeglogene Autotemcel? Betibeglogene Autotemcel is a gene therapy drug product designed to treat transfusion-dependent beta-thalassemia. It involves modifying a patient's own blood stem cells with a functional beta-globin gene to help produce healthy red blood cells.
  • What is the main objective of this clinical trial? The main objectives are to monitor the long-term safety and efficacy of Betibeglogene Autotemcel in patients with transfusion-dependent beta-thalassemia who have been treated in previous bluebird bio-sponsored clinical studies.
  • How long will patients be followed in this study? Patients will be followed for an extended period, with data collected at various time points, including 5 years, 10 years, and 15 years after receiving the drug product.
  • What are some of the key outcomes being measured? Key outcomes include the number of patients achieving transfusion independence, changes in hemoglobin levels, reduction in blood transfusion requirements, iron burden, and quality of life measures.
  • Who is eligible to participate in this study? Eligible participants are those who have been treated with Betibeglogene Autotemcel for transfusion-dependent beta-thalassemia in a previous bluebird bio-sponsored clinical study and have provided informed consent.

Ongoing Clinical Trials on Betibeglogene Autotemcel

  • Long-Term Safety and Efficacy Study of Betibeglogene Autotemcel Gene Therapy for Patients with Transfusion-Dependent Beta-Thalassemia

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Greece Italy

Glossary

  • Beta-thalassemia: A genetic blood disorder that reduces the production of hemoglobin, leading to severe anemia and requiring regular blood transfusions.
  • Gene therapy: A technique that uses genes to treat or prevent disease, often by inserting a functional gene into cells to replace a faulty gene.
  • Autologous: Derived from the same individual, in this case, referring to the patient's own cells used in the treatment.
  • Hematopoietic stem cells: Blood-forming stem cells found in bone marrow that can develop into all types of blood cells.
  • Lentiviral vector: A modified virus used to deliver genetic material into cells for gene therapy purposes.
  • Transfusion independence: The ability to maintain adequate hemoglobin levels without requiring blood transfusions.
  • Hemoglobin (Hb): A protein in red blood cells that carries oxygen throughout the body.
  • Chelation therapy: A treatment to remove excess iron from the body, often necessary for patients receiving frequent blood transfusions.
  • Dyserythropoiesis: Abnormal production of red blood cells.
  • Quality of life (QoL): A measure of an individual's overall well-being and ability to function in daily life.

References

  1. http://clinicaltrials.eu/trial/long-term-safety-and-efficacy-study-of-betibeglogene-autotemcel-gene-therapy-for-patients-with-transfusion-dependent-beta-thalassemia/